Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.

  title={Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.},
  author={Takamitsu Nakamura and Jun-ei Obata and Mitsumasa Hirano and Yoshinobu Kitta and Daisuke Fujioka and Yukio Saito and Ken-ichi Kawabata and Kazuhiro Watanabe and Yosuke Watanabe and Hideto Mishina and Kiyotaka Kugiyama},
  volume={218 1},

Figures and Tables from this paper

High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome.

RLP-C is useful for risk assessment of secondary cardiovascular events in patients treated with statins after ACS and its addition to traditional risk factors enhanced net reclassification improvement (NRI) and integrated discrimination improvement (IDI).

Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease

NAFLD was independently associated with higher circulating RLP-C, and that high R LP-C levels were predictive of MACCE in patients with NAFLD, a prospective observational cohort study carried out.

Differences in lipid parameters among statins treated patients with coronary arteriosclerosis – a pilot study

Univariate analysis showed that the TC/apoB100 ratio was significantly lower in patients with haemodynamically significant stenosis of coronary arteries than in matched patients without coronary artery lesions, and multivariate analysis found that in the group with hypolipidaemic therapy and/or with treatment LDL target (70–100 mg/dL) the TC’s ratio was associated with coronary artery stenosis.

Echolucency of carotid plaque is useful for assessment of residual cardiovascular risk in patients with chronic coronary artery disease who achieve LDL-C goals on statin therapy.

Measurement of echolucency of the carotid artery was useful for assessment of residual coronary risk in CAD patients after LDL-C goal attainment on statin treatment.

Intravascular ultrasound morphology of culprit lesions and clinical demographics in patients with acute coronary syndrome in relation to low-density lipoprotein cholesterol levels at onset

There was no relationship between the LDL-C level at onset and culprit-plaque IVUS morphologies in ACS patients, although culprit plaque in the low-LDL-C ACS group was more vulnerable than in theLow-LDC stable angina group, and diabetes with atherogenic dyslipidemia might be the key residual risk.

The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes

It is demonstrated that higher RC levels were significantly associated with the worse prognosis in DM and pre-DM patients with CAD, suggesting that RC may be a target for patients with impaired glucose metabolism.



Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.

Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events

In patients with established coronary heart disease, increased levels of remnants of triglyceride-rich lipoproteins and decreased levels of high-density lipoprotein cholesterol appear to promote progression of coronary artery atherosclerosis, which in turn may lead to an untoward clinical event.

Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT–TIMI 22

In the present study of ACS patients receiving statin therapy, on-treatment apoB/AI, TC/HDL, and non–HDL-C offered similar prognostic information to LDL-C, however, the addition of hs-CRP to lipid-based measurements significantly improved risk prediction.